DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
ZZ-FIRST
A randomized phase 2
trial of enzalutamide and talazoparib in metastatic
hormone-naïve prostate cancer
PROSTATE
ASCO
2026
CADILLAC
Camizestrant plus ribociclib in hormone receptor-positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial
BREAST
ASCO
2026
ADELA
Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
BREAST
ASCO
2026
PHERGAIN2
A Chemotherapy-Free, Pathological Response-Adapted Strategy Using Trastuzumab-Pertuzumab and T-DM1 in HER2-Positive Early Breast Cancer: the PHERGAIN-2 study”
BREAST
Annals of Oncology
2026
PHERGAIN
SUBSTUDY - PHERGuide: 5-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in HER2[+] early breast cancer (EBC) patients (pts)
BREAST
ESMO Breast
2026
PATHFINDER
Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial
BREAST
Breast Cancer Research
2025
ATRACTIB
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment 1 of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
BREAST
Nature Medicine
2025
DEBBRAH
SUBSTUDY - CEBBRAH: Translational analysis of cerebrospinal fluid (CSF) and plasma circulating tumor DNA (ctDNA) from breast cancer patients (pts) with leptomeningeal disease (LMD) treated with trastuzumab deruxtecan (T-DXd) in the DEBBRAH trial
BREAST
SABCS
2025
TUXEDO-3
Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: results from the TUXEDO-3 phase II trial
BREAST, LUNG AND LMS
ASCO
2025
PARSIFAL LONG
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial
BREAST
ESMO Open
2025
PHENOMENAL
Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: the PHENOMENAL phase 2 study
BREAST
European Journal of Cancer
2025
PECATI
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients
THYMIC
(Journal) The Lancet
2025
Other MEDSIR related articles
